Inflammation, inflammatory mediators, and mediator antagonists in asthma

Journal of Clinical Pharmacology

Volumn 38, Issue 7, 1998, Pages 577-582

  Lazarus, Stephen C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BECLOMETASONE; BUDESONIDE; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FLUTICASONE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 4; LEUKOTRIENE; MONOCLONAL ANTIBODY; NEDOCROMIL SODIUM; TRIAMCINOLONE;

ANTIGEN PRESENTING CELL; ASTHMA; BRONCHOSPASM; CHEMOTAXIS; INFLAMMATION; MAST CELL; MORBIDITY; MORTALITY; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; REVIEW; STANDARDIZATION;

EID: 0031879375     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04463.x     Document Type: Review

References (74)

1. Weiss KB, Gergen PJ, Hodgson TA: An economic evaluation of asthma in the United States. N Engl J Med 1992;326:862-866.
2. Weiss KB: National Asthma Education and Prevention Program Task Force report on the cost effectiveness, quality of care, and financing of asthma care. Am J Respir Crit Care Med 1996;154 (suppl):S81-S130.
3. Gergen PJ, Mullally DI, Evans R: National survey of prevalence of asthma among children in the United States, 1976 to 1980. Pediatrics 1988;81:1-7.
4. Aberg N: Asthma and allergic rhinitis in Swedish conscripts. Clin Exp Allergy 1989;19:59-63.
5. Burney PG, Chinn S, Rona RJ: Has the prevalence of asthma increased in children? Evidence from the national study of health and growth 1973-1986. Br Med J 1990;300:1306-1310.
6. Burr ML: Is asthma increasing? J Epidemiol Community Health 1987;41:185-189.
7. Centers for Disease Control: Asthma: United States, 1980-1990. JAMA 1992;268:1995-1999.
8. Dunnill MS: The pathology of asthma, with special reference to changes in the bronchial mucosa. J Clin Invest 1960;13:27-33.
9. Reed CE: Eosinophils in asthma. I. History and histogenesis. In, Makino S, Gukuda T (eds.): Eosinophils: Biological and Clinical Aspects. Boca Raton, FL: CRC Press, 1993;325-328.
10. Liu MC, Bleecker ER, Lichtenstein LM, Kagey-Sobotka A, Niv Y, McLemore TL, et al: Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am Rev Respir Dis 1990;142:126-132.
11. Laitinin LA, Laitinin A, Haahtela T: Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 1993;147:697-604.
12. Pesci A, Foresi A, Bertorelli G, Chetta A, Oliveri D: Histochemical characteristics and degranulation of mast cells in epithelium and lamina propria of bronchial biopsies from asthmatic and normal subjects. Am Rev Respir Dis 1993;147:684-689.
13. Kay AB: Asthma and inflammation. J Allergy Clin Immunol 1991;87:893-911.
14. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, et al: Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298-304.
15. Pauwel RW: New aspects of the therapeutic potential of theophylline in asthma. J Allergy Clin Immunol 1989;83:548-553.
16. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffrey P, Costello J: Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994;343:1006-1008.
17. Kidney J, Dominguez M, Taylor P, Rose M, Chung K, Barnes P: Immunomodulation by theophylline in asthma. Am J Respir Crit Care Med 1995;151:1907-1914.
18. Kraan J, Koeter GH, Mark TWVD: Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol 1985:76:628-636.
19. Kerrebijn KF, van Ess-Zandvliet EM, Neijens HJ: Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol 1987;79:653-659.
20. Cherniak RM and the North American Tilade Study Group: A double-blind multicenter group comparative study of the efficacy and safety of nedocromil sodium in the management of asthma. Chest 1990;97:1299-1306.
21. Haahtela T, Järvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al: Comparison of a β2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991;325:388-392.
22. Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls A, Roche WR, et al: Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992; 145:669-674.
23. Jeffery PK, Godfrey RW, Adelroth E, Nelson F, Rogers A, Johansson SA: Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma: a quantitative light and electron microscopic study. Am Rev Respir Dis 1992;145:890-899.
24. Laitinen LA, Laitinen A, Haahtela T: A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992;90:32-42.
25. Sheffer AL: National Asthma Education Program Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: Office of Prevention, Education, and Control, National Heart, Lung, and Blood Institute, 1991.
26. Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention (NHLBI/WHO Workshop Report). Bethesda, MD: National Heart, Lung, and Blood Institute, 1995.
27. National Asthma Education Program Expert Panel: Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 1997.
28. Busse WW: What role for inhaled steroids in chronic asthma. Chest 1993;104:1565-1571.
29. Booth H, Richmond I, Ward C, Gardiner PV, Harkawat R, Walters EH: Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Am J Respir Crit Care Med 1995; 152:45-52.
30. Duddridge M, Ward C, Hendrick DJ, Walters EH: Changes in bronchoalveolar lavage inflammatory cells in asthmatic patients with high dose inhaled beclomethasone propionate. Eur Respir J 1993;6:487-497.
31. Dutoit JI, Salome CM, Woolcock AJ: Inhaled corticosteroids reduce the severity of bronchial hyperresponsiveness in asthma but oral theophylline does not. Am Rev Respir Dis 1987;136: 1174-1178.
32. Levy J, Zalkinder I, Kuperman O, Skibin A, Apte R, Bearman JE, Mielk PW, Tal A: Effect of prolonged use of inhaled steroids on the cellular immunity of children with asthma. J Allergy Clin Immunol 1995;95:806-812.
33. McGill KA, Joseph B, Busse WW: Corticosteroids in the treatment of asthma. Clin Immunother 1995;4:16-48.
34. Kamada AK, Szefler SJ, Martin RJ, Boushey HA, Chinchilli VM, Drazen JF, et al: Inhaled glucocorticoids: current issues influencing asthma therapy. Am J Respir Crit Care Med 1996;153: 1739-1748.
35. Kellaway CH, Trethewie RE: The liberation of a slow reacting smooth muscle stimulating substance of anaphylaxis. Q J Ext Physiol 1940;30:121-145.
36. Samuelsson B: Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220:568-575.
37. Piper PJ: Formation and actions of leukotrienes. Physiol Rev 1984;64:744-761.
38. Smith LJ, Greenberger DA, Patterson R, Krell RD, Bernstein PR: The effect of leukotriene D4 in humans. Am Rev Respir Dis 1985;131:368-372.
39. 4 and to methacholine in patients with asthma and normal controls. N Engl J Med 1986; 315:480-484.
40. Drazen JM: Inhalation challenge with sulfidopeptide leukotrienes in human subjects. Chest 1986;89:414-419.
41. Marom Z, Shelhamer JH, Back MK, Morton DR, Kaliner M: Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982;126:449-451.
42. Lazarus SC, McCabe LJ, Nadel JA, Gold WM, Leikauf GD: Effects of mast cell-derived mediators on epithelial cells in canine trachea. Am J Physiol 1986;251:C387-C394.
43. Dahlén SE, Bjork J, Hedqvist P: Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci U S A 1981;78:3887-3891.
44. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJH: Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980;286:264-265.
45. Krell RD, Dehaas CJ, Lengel DJ, Kusner EJ, Williams JC, Buckner CK: Preclinical exploration of the potential antiinflammatory properties of the peptide leukotriene antagonist ICI 204,219 (Accolate). Ann N Y Acad Sci 1994;744:289-298.
46. Dahlén S-E, Hedqvist P, Hammarström S, Samuelsson B: Leukotrienes are potent constrictors of human bronchi. Nature 1980; 288:484-486.
47. Hanna CJ, Bach MK, Pare PD, Schellenberg RR: Slow reacting substances (leukotrienes) contract human airway and pulmonary vascular smooth muscle in vitro. Nature 1981;290:343-344.
48. Zakrzewski JT, Barnes NC, Piper PJ, Costello JF: Measurement of leukotrienes in arterial and venous blood from normal and asthmatic subjects by radioimmunoassay (abstract). Br J Clin Pharmacol 1985;19:574P.
49. Shaw RJ, Fitzharris P, Cromwell O, Wardlaw AJ, Kay AB: Allergen-induced release of sulphidopeptide leukotrienes (SRS-A) and LTB4 in allergic rhinitis. Allergy 1985;40:1-6.
50. Creticos PS, Peters SP, Adkinson NF, Naclerio RM, Hayes EC, Norman PS, Lichtenstein LM: Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med 1984;310:1626-1630.
51. Taylor GW, Taylor I, Black P, Maltby NH, Turner N, Fuller RW, Dollery CT: Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989;1:584-588.
52. 4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 1990;142:112-119.
53. Wenzel SE, Westcott JY, Larsen GL: Bronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: relationship to the development of late asthmatic responses. J Allergy Clin Immunol 1991;87:540-548.
54. 4 in humans: effect of indomethacin. Am Rev Respir Dis 1990;141:1441-1445.
55. 4 from the urine of patients with airway obstruction. Am Rev Respir Dis 1992;146: 104-108.
56. Dixon RAF, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, et al: Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990;343:282-284.
57. Findlay SR, Barden JM, Easley CB, Glass M: Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced broncho-constriction in subjects with asthma. J Allergy Clin Immunol 1992;89:1040-1045.
58. Lazarus SC, Wong HH, Watts MJ, Boushey HA, Lavins BJ, Minkwitz MC: The leukotriene receptor antagonist, zafirlukast, inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma. Am J Resp Crit Care Med 1997;156:1725-1730.
59. Israel E, Demarkarian R, Rosenberg M, Sperling R, Taylor G, Rubin P, Drazen JM: The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Medicine 1990;323: 1740-1744.
60. Finnerty JP, Wood-Baker R, Thomson H, Holgate ST: Role of leukotrienes in exercise-induced asthma: inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis 1992;145:746-749.
61. Israel E, Fischer AR, Rosenberg MA: The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993;148:1447-1451.
62. Israel E, Rubin P, Kemp J, Grossman J, Pierson W, Siegel SC, et al: The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993;119:1059-1066.
63. Dahlén B, Margolskee DJ, Zetterstrom O, Dahlén SE: Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 1993;48:1205-1210.
64. Hui KP, Barnes NC: Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991;337: 1062-1063.
65. Gaddy JN, Margolskee DJ, Bush RK, Williams VC, Busse WW: Bronchodilation with a potent and selective leukotriene D4 receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis 1992;146:358-363.
66. Impens N, Reiss TF, Teahan JA, Desmet M, Rossing TH, Shingo S, et al: Acute bronchodilatation with an intravenously administered leukotriene D4 antagonist, MK-679. Am Rev Respir Dis 1993;147:1442-1446.
67. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994;150:618-623.
68. Cloud MC, Enas GC, Kemp J, Platts-Mills T, Altman LC, Townley R, et al: A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am Rev Respir Dis 1989;140:1336-1339.
69. Israel E, Cohn J, Dubé L, Drazen JM, and the Zileuton Clinical Trial Group: Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. JAMA 1996;275:931-936.
70. Suissa S, Dennis R, Ernst P, Sheehy O, Wood-Dauphinee S: Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997;126:177-183.
71. Louis R, Shute J, Biagi S, Stanciu L, Marrelli F, Tenor H, et al: Cell infiltration, ICAM-1 expression, and eosinophil chemotactic activity in asthmatic sputum. Am J Respir Crit Care Med 1997; 155:466-472.
72. Gonokami Y, Konno S, Kurokawa M, Kawazu K, Ueno K, Tomita K, et al: Circulating intracellular adhesion molecule-1 concentrations following bronchial provocation in atopic asthma. Int Arch Allergy Immunol 1997;112:386-391.
73. Wegner CD, Gundel RH, Reilly P, Haynes N, Letts LG, Rothlein R: Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. Science 1990;247:456-459.
74. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, et al: The effect of an anti-IgE monoclonal antibody on the early-and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-1834.